Novartis CEO: Some Cancer Drugs Dropped From Pipeline Because of Medicare Price Negotiations
- May 19, 2023
- 1 min read
Novartis has dropped some early-stage cancer drugs from its pipeline because Medicare’s new ability to negotiate certain drug prices will make them no longer worthwhile for the company, according to...